Martin’s Point Health Care to pay $22.5M to settle false claims case
By 
Jeff Dale2023-07-31T18:55:00
A Maine-based healthcare provider will pay nearly $22.5 million to settle allegations it violated the False Claims Act by knowingly submitting inaccurate diagnosis codes for Medicare enrollees to increase reimbursements.
Martin’s Point Health Care, which operates Medicare Advantage plans for beneficiaries living in Maine and New Hampshire, allegedly submitted risk scores for patients that did not match their medical records, the Department of Justice (DOJ) said in a press release Monday.
The settlement resolves a lawsuit brought under the qui tam provisions of the False Claims Act by Alicia Wilbur, a former manager in the risk adjustment operations group at Martin’s Point. Wilbur will receive approximately $3.8 million.
THIS IS MEMBERS-ONLY CONTENT
You are not logged in and do not have access to members-only content.
If you are already a registered user or a member, SIGN IN now.
Related articles
-
News BriefDermatology manager to pay $8.9M in self-reported false claims case
Oliver Street Dermatology Management, doing business as U.S. Dermatology Partners, agreed to pay nearly $8.9 million to settle allegations by the Department of Justice regarding apparent violations of the False Claims Act.
-
News BriefLincare to pay $29M over false claims for improperly billing Medicare
Lincare Holdings, a provider of oxygen equipment and subsidiary of Linde, agreed to pay $29 million to resolve allegations it violated the False Claims Act by fraudulently overbilling Medicare.
-
News BriefBooz Allen to pay $377.5M in improper billing case
Booz Allen Hamilton agreed to pay approximately $377.5 million as part of a settlement with the Department of Justice regarding alleged False Claims Act violations stemming from improper billing of commercial and international costs in government contracts.
More from Regulatory Enforcement
-
ArticleU.K. competition regulator ‘very likely’ to use new enforcement powers despite government’s pro-growth agenda
New powers granted to the U.K.’s main competition watchdog will result in greater scrutiny, tougher enforcement, and a stark warning for companies to review their sales and marketing promotions—especially since some practices have been pushed firmly into the spotlight thanks to legislation that came into effect last year.
-
ArticleSEC enforcement priorities revert back to basics
Recent pronouncements made by the U.S. Securities and Exchange Commission leadership, alongside the recent overhaul of the SEC Enforcement Manual, collectively signal a back-to-basics enforcement approach that appears beneficial for companies in their dealings with the agency.
-
ArticleFCA drive to reduce its investigation costs likely to add to compliance burden for smaller firms, warn experts
The U.K. financial regulator’s move towards “impactful deterrence” could see smaller and mid-size firms come increasingly under the spotlight as the watchdog aims to tackle market-wide concerns instead of primarily focusing on large players capable of doing the most harm.